City Therapeutics raises $99.5M Series B to advance three RNAi candidates into the clinic and expand its delivery platform beyond the liver.
City Therapeutics, the next-gen RNAi startup founded and led by former Alnylam executives, has collected $99.5 million to fund the clinical development of its first …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
City banks nearly $100M for next-gen RNAi drugs
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion - Alnylam Pharmaceuticals (
Alnylam, Inceptive ink AI deal potentially worth $2B
AI titans push Congress for DNA safeguards
Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
Novo underwhelmed by drug it once fought Pfizer for
Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An…
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Alnylam will pay $30 million upfront for its first discovery-focused AI deal, tapping a Silicon Valley biotech startup to see if…
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
SonoThera has secured another $125 million to take its ultrasound-based gene therapy technology into the clinic.
Alnylam announced a three-year deal with Inceptive Nucleics, worth up to $2 billion, with $30 million upfront in cash and equity…
